Vortioxetine Treatment for Depression in Alzheimer’s Disease: A Randomized, Double-blind, Placebo-controlled Study

• DOI: 10.9758/cpn.2022.20.2.311
• Publication Date: 2022-04-25T05:56:05Z
• Authors: Hye Won Jeong; Kyung Hee Yoon; Chang Hyun Lee; Yoo Sun Moon; Do Hoon Kim
• Keywords: Vortioxetine; Tolerability; Discontinuation; Depression

Vortioxetine, a new antidepressant, has been demonstrated to have effects on depression and cognitive function. This study aimed investigate the anti-depressive efficacy of vortioxetine through well-designed double- blind, placebo-controlled in Alzheimer's disease (AD) patients, confirm presence secondary benefits, including improvement function activities daily living (ADL).The present included 100 AD patients with who were assigned randomly 12 weeks treatment either or placebo. The primary measure was change Cornell Scale for Depression Dementia score from baseline weeks. Several measures evaluated, Korean version Short form Geriatric several domains. safety tolerability also assessed. We performed modified intention-to-treat analysis using mixed modeling (the Mixed Models Repeated Measures).There no statistically significant difference between two groups terms depressive symptoms, functions, ADL. Further, percentage adverse events drug discontinuation placebo similar.Our results suggest that might not be effective reducing symptoms impairment depression. However, general tolerance patient similar those Thus, additional studies are needed replicate effectiveness